Compounds > nps-568
Page last updated: 2024-09-04

nps-568 and Hyperparathyroidism, Primary

nps-568 has been researched along with Hyperparathyroidism, Primary in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nagano, N1
de Vernejoul, MC; Legoupil, N; Ureña, P1

Reviews

2 review(s) available for nps-568 and Hyperparathyroidism, Primary

ArticleYear
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Pharmacology & therapeutics, 2006, Volume: 109, Issue:3

    Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing

2006
[Calcimimetics, mechanisms of action and therapeutic applications].
    Presse medicale (Paris, France : 1983), 2005, Sep-10, Volume: 34, Issue:15

    Topics: Aniline Compounds; Animals; Bone Remodeling; Calcium; Cells, Cultured; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Time Factors; Uremia

2005